Content by Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced the launch of the Bio-Plex™ Pro Human SARS-CoV-2 Variant Neutralization Antibody Assays, for research use only (RUO).

StarBright UltraViolet 400 Dye Offers Maximal Brightness and Narrow Excitation and Emission Profiles for Precise Resolution

The CFX Opus 96 Dx System and the CFX Opus 384 Dx Real-Time PCR Systems Offer Accurate and Precise Quantification to Improve IVD Assay Development and Diagnostic Testing

Bio-Rad experts Eddy van Collenburg and Jörg Bantin will discuss where your research can greatly benefit from using ddPCR rather than qPCR, as well as how to ensure a seamless transition to ddPCR.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of the SEQuoia RiboDepletion Kit, which improves assay efficiency by eliminating irrelevant ribosomal RNA (rRNA) fragments from an RNA-Seq library.

The Qualitative Multiplex Immunoassay Panel Provides Precise, Specific, and Sensitive Detection of IgG Antibodies Against Four SARS-CoV-2 Antigens

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products announced the global launch of its CFX Opus 96 and CFX Opus 384 Real-time PCR Systems along with BR.io, a cloud-based instrument connectivity, data management, and analysis platform.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its CFX96 Dx Real-Time PCR System has been listed with the U.S. Food and Drug Administration (FDA) for IVD testing and may be used to help in the diagnosis of COVID-19.

Bio-Rad Laboratories Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its SARS-CoV-2 Droplet Digital PCR (ddPCR) test kit has been granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA). 

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of a range of anti-certolizumab pegol inhibitory antibodies to support the development of assays for therapeutic drug monitoring of tumor necrosis factor (TNF) alpha inhibitors.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it was granted U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for the company's SARS-CoV-2 Total Ab test, the first total antibody test receiving EUA from the FDA. Bio-Rad's blood-based immunoassay test can help clinicians identify if an individual has developed antibodies against SARS-CoV-2, the virus associated with COVID-19 disease. 

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that in two studies published this month, ahead of peer-review, researchers in China reported that Bio-Rad’s QX200 Droplet Digital PCR (ddPCR) System showed superior sensitivity and precision for clinical detection of SARS-CoV-2 (the virus that causes COVID-19) compared to existing test methods that are performed using qPCR.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of the SEQuoia Complete Stranded RNA Library Prep Kit, a novel approach to RNA-Seq library preparation.